English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To assess the impact of faster aspart vs insulin aspart on long‐term clinical outcomes and costs for patients with type 1 diabetes mellitus ( T1DM ) in the  UK  setting.    Methods  The  QuintilesIMS CORE D iabetes Model was used to project clinical outcomes and costs over patient lifetimes in a cohort with data on baseline characteristics from the “onset 1” trial. Treatment effects were taken from the 26‐week main phase of the onset 1 trial, with costs and utilities based on literature review. Future costs and clinical benefits were discounted at 3.5% annually.    Results  Projections indicated that faster aspart was associated with improved discounted quality‐adjusted life expectancy (by 0.13 quality‐adjusted life‐years) vs insulin aspart. Improved clinical outcomes resulted from fewer diabetes‐related complications and a delayed time to their onset with faster aspart. Faster aspart was found to be associated with reduced costs vs insulin aspart (cost savings of £1715), resulting from diabetes‐related complications avoided and reduced treatment costs.    Conclusions  Faster aspart was associated with improved clinical outcomes and cost savings vs insulin aspart for patients with  T1DM  in the  UK  setting.

diabetes, obesity and metabolism

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the  UK  setting